Nervgen Pharma NGEN

NervGen Pharma Corp is a clinical stage biopharmaceutical company focused on the discovery development and commercialization of neuroreparative therapeutics that aim to enable the nervous system to repair itself. Its lead drug candidate NVG 291 is a humanized peptide targeting the proteoglycan receptor protein tyrosine phosphatase sigma and is being evaluated in a Phase 1b/2a clinical trial called the CONNECT SCI Study for individuals living with spinal cord injury. The company also holds intellectual property for a second compound NVG 300 and is using its technology platform to explore additional neurologic indications such as traumatic brain injury stroke and hearing loss. The company's approach centers on blocking the activity of the leukocyte common antigen related LAR family of receptor protein tyrosine phosphatases which are upregulated after neurologic injury and inhibit axonal regeneration. By inhibiting these receptors NVG 291 aims to promote neuronal sprouting remyelination and a non inflammatory microglial response thereby supporting functional recovery.

NervGen Pharma Corp does not currently generate operating revenues from product sales or services. The company has not commercialized any products and reports no product related income. Its only source of revenue consists of interest earned on its cash and cash equivalents. Future revenue could arise from the sale of approved therapies licensing arrangements or collaboration partnerships if its drug candidates succeed in clinical development and obtain regulatory approval.

NervGen Pharma Corp occupies a niche within the biopharmaceutical industry as a developer of first in class neurorepair therapies for spinal cord injury and related neurologic conditions. There are presently no approved treatments that restore nervous system function after injury which creates a significant unmet medical need. According to data referenced in the filing approximately 312,000 Americans are living with spinal cord injury and about 18,500 new cases occur each year in the United States. The company has secured regulatory incentives including Fast Track designation from the US Food and Drug Administration and Orphan Drug Designation from the European Medicines Agency for its lead candidate NVG 291. These distinctions together with its exclusive worldwide license to the underlying LAR family phosphatase blocking peptide technology provide potential competitive advantages over other entities working in the spinal cord injury space.

The company intends to serve patients suffering from spinal cord injury and other neurologic disorders such as traumatic brain injury stroke and hearing loss. Its future customers would include hospitals rehabilitation centers and specialty clinics that would administer its therapies once approved as well as the patients and their caregivers who would benefit from restored neurological function.